VERISTAT

Cardiovascular Disease Development Expertise

Veristat is passionate about advancing breakthrough therapies that treat and manage cardiovascular disease. Our end-to-end clinical trial consultation, operations and regulatory solutions span trial design and execution through to regulatory submission.

>100 cardiovascular trials

5 regulatory submissions

>30 rare cardiovascular disease trials

Cardiology Experience by Product Type



Cardiology Trials by Phase



Overall Cardiology Experience

✓ Abdominal aortic aneurysms	✓ Homozygous Familial Hypercholesterolemia (HoFH)
✓ Acute hereditary angioedema attacks	✓ Iliac stent
✓ Arteriosclerosis	✓ Imaging for heart failure
✓ Blood loss prevention in cardiac surgery	✓ Ischemic heart disease
✓ Congenital heart disease	✓ Self-expanding carotid stent
✓ Coronary arterial restenosis	✓ Vascular access grafts
✓ Coronary artery disease/CABG	✓ Vascular injury
✓ Deep Vein Thrombosis (DVT)	✓ Venipuncture device

Clinical Staff Experience

42% of our staff have worked on a cardiology trial

>65% of our staff have advanced degrees

Veristat Cardiology Team Members	Average Industry Experience
Biostatisticians & Programmers	>13 years
Data Managers	>13 years
Medical Writers	>20 years
Project Managers	>16 years

CASE STUDY

Early Achievement of Patient Enrollment Timelines

Completion of Early Patient Enrollment for a Hypertension Trial Allowing Sponsor to Start Up Two Additional Studies

Situation: A clinical-stage biotechnology start-up asked Veristat to run their Phase II study for a topical spray to treat hypertension. Veristat had already completed a study for this product in another indication, which showed evidence that the product reduced elevated blood pressure. Our sponsor was eager to get a second study up and running quickly to see if this product worked for the treatment of hypertension.

Solution: Veristat accelerated the proposal to kick-off meeting timeline, completing it in under six weeks. We assembled a strong clinical operations team, consisting of the project manager, lead clinical research associate (CRA), regional CRAs and clinical trial associates, as well as a lead statistician, data manager, medical writer and safety manager. The team started work immediately on feasibility & study setup requirements and prepared timelines to quickly open the 10 sites participating in the study. The first patient entered the study in early December, a full two months earlier than anticipated. Site close and preparation of the clinical study reports (CSRs) were achieved by end of the second year.

Impact: Due to the success of this project, the client decided to accelerate the start-up of two additional studies for the same product in different therapeutic areas with Veristat, the first of which is now underway.

> *"We are very happy with the progress that the Veristat team has made on our Phase II study in hypertension, having met the enrollment timelines earlier than planned. I continue to be impressed with the strength and breadth of therapeutic experience of my team and value their dedication to our success, transparent communications, and expert management of my studies."*

President, Biotech Firm

Contact Veristat Today

Learn more about Veristat and how we can assist you with your cardiology trial development, execution, and regulatory submission preparation.

www.veristat.com